Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 28, 2017
Pharmacy Choice - News - Pharmaceutical Development - May 28, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/28/17 - `Outstanding` results announced from new blood cancer study [Tehran Times (Iran)]
-Professor Martin Dyer, University of Leicester. The advance led by a team from the University of Leicester and University Hospitals of Leicester NHS Trust, within the Hope Clinical Trials Facility, focused on treating patients with CLL. The study opened in January 2012 and 90 patients were enrolled in different centres in the UK and in France, wit
4/28/17 - ABIVAXConfirms Trading Suspension
ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the suspension of trading on Euronext Paris effective as of April 28, 2017 at 11:29am CEST. ABIVAX also confirms that the results of ABX464-004, the 2 nd Phase IIa clinical trial of ABX464, its lead drug candidate in the treatment of HIV, w
4/28/17 - Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex?
Aeterna Zentaris Inc. will announce the top-line results of the ZoptEC Phase 3 clinical study of Zoptrex? in women with locally advanced, recurrent or metastatic endometrial cancer prior to the commencement of trading on Monday, May 1, 2017. The Company will host a conference call to discuss the results of the ZoptEC Phase 3 clinical study of Zop
4/28/17 - Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Womens Health [Sport360]
-Agile Therapeutics, Inc., a women`s healthcare company announced today that a presentation entitled An Update on Hormonal Contraception and The Changing U.S. Population will be presented by Co-Principal Investigator of the SECURE clinical trial, Anita Nelson, MD, Professor and Chair, Obstetrics and Gynecology, College of Osteopathic Medicine of th
4/28/17 - Alder BioPharmaceuticals Presents Positive Phase 2b Study Data for Eptinezumab at 69th Annual American Academy of Neurology Meeting
Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the presentation of positive data from its Phase 2 b clinical trial evaluating eptinezumab for the prevention of migraine. These data and additional study results are the topic of a podium presentation titled.
4/28/17 - Align Biopharma Announces New Identity Management Standard Available for Life Sciences Industry Input
By a News Reporter-Staff News Editor at Drug Week Align BiopharmaTM, a life sciences industry standards group that includes eight of the top 20 global pharmaceutical companies, announced its first technology standard is available for industrywide review and input. Therefore, the group is soliciting public review and input for its identity managem
4/28/17 - ANDA approval times should be cut by two-thirds [Syrian Arab News Agency]
Girish Malhotra, President of EPCOT International, and CPhI Worldwide Annual Industry Report member, discusses the necessity of time reduction for Abbreviated New Drug Application approvals. This time can potentially be reduced to 15 days if the FDA modifies their review process. To avoid confusion, the FDA would have to create applications that cl
4/28/17 - Aspyrian announces the presentation of clinical data of its investigational therapy RM-1929 demonstrating significant anti-cancer response in recurrent Head and Neck Cancer patients who have failed all existing treatment options
Aspyrian Therapeutics, Inc., a biotechnology company developing precision-targeted cancer therapies based on the proprietary Photoimmunotherapy platform, today announced that findings from an ongoing clinical trial of its proprietary investigational compound, RM-1929, were presented at the American Head& Neck Society meeting, April 27, in San Die
4/28/17 - AstraZenecas lung cancer drug receives full approval in the EU [Sudan Tribune]
The European Commission has granted full marketing authorisation for AstraZenecas Tagrisso for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer. The full approval for Tagrisso is based on the results of the Phase III AURA3 trial.
4/28/17 - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Scores Big, But Have The Children?
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a big end of the week winner this week, with the company soaring on the back of an FDA approval announcement. There's more to it than the approval, however. The company also picked up a voucher from the agency that will set it at a distinct advantage to some of [?] The post BioMarin Pharmaceutical I
4/28/17 - BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update
NESS ZIONA, Israel, April 28, 2017/ PRNewswire/ BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today announced its fourth quarter and full year financial results for the year ended December 31, 2016, and provided a business update.
4/28/17 - Capsule Endoscopy Market 2017 Global Trends, Size, Share, Strategy, Segmentation Analysis by Forecast to 2027
Fujifilm Holding Corporation, Given Imaging Ltd./ Medtronic, Olympus America IntroMedic Co. Ltd. " Market Research Future PUNE, MAHARASHTRA, INDIA, April 28, 2017/ EINPresswire.com/ Market Highlights: Globally the market for Capsule Endoscopy is increasing rapidly. Furthermore increasing use of digital technology in medical devices and increasi
4/28/17 - CEMPRA, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operation
In December 2016, we received a complete response letter, or CRL, from the U.S. Food and Drug Administration, or FDA, on our NDAs. The CRL stated that the FDA could not approve the NDAs in their present form and noted that additional clinical safety information and the satisfactory resolution of manufacturing facility inspection deficiencies were r
4/28/17 - Checkpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co. [Tehran Times (Iran)]
-Checkpoint Therapeutics, Inc., a Fortress Biotech company, today announced that James F. Oliviero, President and CEO of Checkpoint, will present a company update at PIONEERS 2017, presented by Joseph Gunnar& Co., on Tuesday, May 2, 2017 at 4:30 p.m. ET. About Checkpoint TherapeuticsCheckpoint Therapeutics, Inc., a Fortress Biotech company, is a cl
4/28/17 - China FDA Approves Country's First All-Oral Regimen for Chronic Hepatitis C, Daklinza (daclatasvir) in Combination with Sunvepra (asunaprevir)
Bristol-Myers Squibb Company announced today that the China Food and Drug Administration has approved a direct-acting antiviral regimen comprised of Daklinza and Sunvepra , for the treatment of treatment-naive or- experienced patients, with or without compensated cirrhosis, infected with genotype 1 b chronic hepatitis C virus.
4/28/17 - Clear Sky Recovery's Ibogaine Treatment Program to be Featured on National Geographic
Addiction: A Psychedelic Cure? will air on the National Geographic Channel on Tuesday, May 2 at 10 p.m. ET/9 p.m. CT.
4/28/17 - Contract Research Organization Market Rising at $59.42 Bn Globally in 2020
Contract Research Organization Market for Early-Stage Development Services and Last-Stage Development Services: Global Industry Perspective, Comprehensive Analysis and Forecast 2014- 2020 Deerfield Beach, FL 04/28/2017 According to the report, global Contract Research Organization market was valued at USD 34.00 billion in 2014 and is expected
4/28/17 - CPAC COX RapidHeat Sterilizer Features FDA-Cleared Rapid Cycles
Wrapped instruments and handpieces are FDA cleared for 12 minutes.
4/28/17 - Creative Biolabs Announces Phage Display Library Screening Service Targeting Various Pharmaceutical Research
Creative Biolabs, a biopharmaceutical company focused on early drug discovery and development, announced its phage display library screening service based on the common efforts of researchers. Having been researching in the field of phage display technology for years, Creative Biolabs is able to offer a series of comprehensive phage display library
4/28/17 - Deep Learning Luminary Yoshua Bengio Joins Recursion Pharmaceuticals as Key Advisor
Recursion Pharmaceuticals, an emerging biotechnology company that combines innovative biological science with machine learning techniques to discover treatments for rare genetic diseases, today announced that Yoshua Bengio will be joining the company as a scientific advisor. In this role, Bengio will further Recursion's machine learning...
4/28/17 - Deltex Medical wins EU grant for blood monitoring product [Syrian Arab News Agency]
Deltex Medical Group, a maker for blood monitoring and fluid management equipment for use in surgical operations, has won a 50,000 grant from the European Union. Deltex, along with Lariboisiere Hospital in Paris, have developed a system which provides simultaneous visual display of a patient`s aortic blood flow velocity and aortic blood pressure ca
4/28/17 - Determination That DEMEROL (Meperidine Hydrochloride) Injectable and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or...
Notice. Citation: "82 FR 19735" Document Number: "Docket No. FDA-2017-N-1551" Page Number: "19735" "Notices" SUMMARY: The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin pro
4/28/17 - FDA approves 1st targeted drug for certain leukemia patients
The Food and Drug Administration approved the drug for adults with acute myeloid leukemia, or AML, who have a genetic mutation called FLT3. Richard Stone of Dana-Farber Cancer Institute in Boston, said in a statement. He led testing of Rydapt, funded by the drug's maker, Novartis Pharmaceuticals Corp. Read more on Colorado Springs Gazette.
4/28/17 - FDA approves first treatment for a form of Batten disease
Release date- 27042017- The U.S. Food and Drug Administration today approved Brineura as a treatment for a specific form of Batten disease. Brineura is the first FDA- approved treatment to slow loss of walking ability in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2, also known as
4/28/17 - FDA approves more drugs, and faster, than Europe, study says [Malta Independent, The]
"It's an urban myth" that the FDA is slower than other countries to clear promising treatments for patients, said the agency's longtime cancer drugs chief, Dr. The new research compared how new drugs fared before the FDA and the European Medicines Agency between 2011 and 2015. The FDA approved more drugs than the Europeans- 170 versus 144- with a m
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415